Study Guide Studium Generale STUDIUM GENERALE AIMS To
... mencapai kesehatan gigi dan mulut masyarakat yang optimal (C3,P3,A3). ...
... mencapai kesehatan gigi dan mulut masyarakat yang optimal (C3,P3,A3). ...
Module 2. Clinical Pharmacy in gastroenterology, hepatology
... 33. Indication for administration of histamine H1 antagonists is: A. Prevention or treatment of the symptoms of allergic reactions (rhinitis, urticaria) B. Motion sickness and vestibular disturbances C. Nausea and vomiting in pregnancy (“morning sickness”) D. * All of the above E. None of the above ...
... 33. Indication for administration of histamine H1 antagonists is: A. Prevention or treatment of the symptoms of allergic reactions (rhinitis, urticaria) B. Motion sickness and vestibular disturbances C. Nausea and vomiting in pregnancy (“morning sickness”) D. * All of the above E. None of the above ...
Up in Smoke - Marijuana Today - Burns M. Brady
... “Marijuana can impair concentration and the ability to retain information during a teen’s peak learning years.” - National Education Association ...
... “Marijuana can impair concentration and the ability to retain information during a teen’s peak learning years.” - National Education Association ...
“FORMULATION & PROCESS DEVELOPMENT OF AZITHROMYCIN OPHTHALMIC NANOSUSPENSION” Research Article
... Objective: The objective of this study was to prepare a novel stable azithromycin ophthalmic nanosuspension which has advantage over conventional ophthalmic suspension such as blurred vision, burning, stinging and irritation upon instillation. The viscosity was increased to provide additional advant ...
... Objective: The objective of this study was to prepare a novel stable azithromycin ophthalmic nanosuspension which has advantage over conventional ophthalmic suspension such as blurred vision, burning, stinging and irritation upon instillation. The viscosity was increased to provide additional advant ...
Medical Fitness to Drive - The Impact of Benzodiazepines Anne
... roads, benzodiazepines are the second most frequent toxicological finding after alcohol. The presence of benzodiazepines in killed drivers ranges from 1.8-13.3% across European countries. With regard to seriously injured drivers, benzodiazepines were present in up to 10.2% of drivers, and were the t ...
... roads, benzodiazepines are the second most frequent toxicological finding after alcohol. The presence of benzodiazepines in killed drivers ranges from 1.8-13.3% across European countries. With regard to seriously injured drivers, benzodiazepines were present in up to 10.2% of drivers, and were the t ...
Antimicrobial activities of tosufloxacin against Streptococcus
... quinolones used for respiratory infections. This is a very important factor for selecting a drug. The incidence of PRSP/PISP among S. pneumoniae increased from 50.9% in the second survey to 59.6% in the third survey, indicating the serious impact of these resistant strains on the clinical use of cep ...
... quinolones used for respiratory infections. This is a very important factor for selecting a drug. The incidence of PRSP/PISP among S. pneumoniae increased from 50.9% in the second survey to 59.6% in the third survey, indicating the serious impact of these resistant strains on the clinical use of cep ...
Gentamicin – Therapeutic drug monitoring
... monitoring aims to avoid both excessive and sub-therapeutic concentration thereby preventing toxicity and ensuring efficacy. The following sections provide detailed instructions on how to dose, monitor and administer these agents. Antibiotic doses should not be withheld pending on antibiotic assays ...
... monitoring aims to avoid both excessive and sub-therapeutic concentration thereby preventing toxicity and ensuring efficacy. The following sections provide detailed instructions on how to dose, monitor and administer these agents. Antibiotic doses should not be withheld pending on antibiotic assays ...
PBG Report – PBI Feldetrex
... • There is no drug that targets the actual condiBon • The pathophysiology and mechanism of the disease is not understood, therefore current treatments target symptoms • Current animal models only display the ...
... • There is no drug that targets the actual condiBon • The pathophysiology and mechanism of the disease is not understood, therefore current treatments target symptoms • Current animal models only display the ...
training workshop on pharmaceutical quality, good manufacturing
... Plasma concentration time profile concentration ...
... Plasma concentration time profile concentration ...
06_Multiple dosing Extravascular Administration
... The ‘‘average’’ plasma concentration of a drug at steady state for extravascularly administered dose can be calculated from: ...
... The ‘‘average’’ plasma concentration of a drug at steady state for extravascularly administered dose can be calculated from: ...
10.4103-0975-1483.93570
... oral drug formulations have been used since the 1960s to enhance performance and increase patient compliance.[1] By incorporating the dose for 24 h into one tablet from which the drug is slowly released, peaks of high plasma concentration and troughs of low plasma concentration can be prevented.[2] ...
... oral drug formulations have been used since the 1960s to enhance performance and increase patient compliance.[1] By incorporating the dose for 24 h into one tablet from which the drug is slowly released, peaks of high plasma concentration and troughs of low plasma concentration can be prevented.[2] ...
Zyvox - Blue Cross Blue Shield of Arizona
... As a result of rising prevalence of MRSA, empiric therapy for hospitalized individuals with ABSSSI usually includes intravenous use of an antimicrobial with activity against MRSA and an agent that has activity for the other possible pathogens. Out-patients may be managed with a cost effective oral a ...
... As a result of rising prevalence of MRSA, empiric therapy for hospitalized individuals with ABSSSI usually includes intravenous use of an antimicrobial with activity against MRSA and an agent that has activity for the other possible pathogens. Out-patients may be managed with a cost effective oral a ...
The Next Generation of Drug-Coated Balloons
... of use over their currently used competitive brand. CLINICAL COMMITMENT Given the challenging biological environment posed by these vessel beds such as the superficial femoral artery (SFA), it is clear that multiple drug-eluting approaches should be explored as the treatment algorithm continues to e ...
... of use over their currently used competitive brand. CLINICAL COMMITMENT Given the challenging biological environment posed by these vessel beds such as the superficial femoral artery (SFA), it is clear that multiple drug-eluting approaches should be explored as the treatment algorithm continues to e ...
Amphetamine withdrawal
... Results: Twenty-two patients took part in each treatment group. The week-1 and week-2 intention-to-treat analyses showed that the mean AWQ reversed vegetative scores (combined scores of decreased energy, increased appetite and craving for sleep items) of the amineptine group were significantly lower ...
... Results: Twenty-two patients took part in each treatment group. The week-1 and week-2 intention-to-treat analyses showed that the mean AWQ reversed vegetative scores (combined scores of decreased energy, increased appetite and craving for sleep items) of the amineptine group were significantly lower ...
AmBisome (amphotericin B) liposome for injection
... 11 patients in the AmBisome group and 7 of 10 in the amphotericin B group. Study 97-0-034, a randomized, double-blind, comparative multi-center trial, evaluated the safety of AmBisome (3 and 5 mg/kg/day) compared with amphotericin B lipid complex (5 mg/kg/day) in the empirical treatment of 202 adult ...
... 11 patients in the AmBisome group and 7 of 10 in the amphotericin B group. Study 97-0-034, a randomized, double-blind, comparative multi-center trial, evaluated the safety of AmBisome (3 and 5 mg/kg/day) compared with amphotericin B lipid complex (5 mg/kg/day) in the empirical treatment of 202 adult ...
Translational Safety in Drug Development
... susceptibility factors for quantitative analysis of interactions between drugs and patients. This involves pharmacokinetics, toxicodynamics, pharmacodynamics and individual subject factors with a focus on populations and variability, Toxicometrics is defined as the science that quantifies drug, toxi ...
... susceptibility factors for quantitative analysis of interactions between drugs and patients. This involves pharmacokinetics, toxicodynamics, pharmacodynamics and individual subject factors with a focus on populations and variability, Toxicometrics is defined as the science that quantifies drug, toxi ...
auranofin - Oxford Academic
... 2 ) and hydroxyl radicals (OH), as well as hydrogen peroxide, with disruption of membrane fluidity. It is not known which of these mechanisms is responsible for the effects on the epithelial cells and the enteric nerves, but the activation of phospholipase C does appear to be a possibility. The abov ...
... 2 ) and hydroxyl radicals (OH), as well as hydrogen peroxide, with disruption of membrane fluidity. It is not known which of these mechanisms is responsible for the effects on the epithelial cells and the enteric nerves, but the activation of phospholipase C does appear to be a possibility. The abov ...
Managing lipids to prevent cardiovascular events
... Patients without clinical ASCVD with LDL levels <190 mg/dL who are 40-75 years old with an elevated 10-year risk of ASCVD may benefit from statins. Assessing risk in this primary prevention population will be discussed in detail below. Individuals younger than 40 years or older than 75 years may als ...
... Patients without clinical ASCVD with LDL levels <190 mg/dL who are 40-75 years old with an elevated 10-year risk of ASCVD may benefit from statins. Assessing risk in this primary prevention population will be discussed in detail below. Individuals younger than 40 years or older than 75 years may als ...
Novel Psychoactive Substances and Other Drugs May 2014
... people who have used these drugs. • More information is available about certain substances than others -this is not an exhaustive list or document. • We have attempted to consolidate as much accurate information as possible, but not all of it is scientifically ...
... people who have used these drugs. • More information is available about certain substances than others -this is not an exhaustive list or document. • We have attempted to consolidate as much accurate information as possible, but not all of it is scientifically ...
infections in patients with cancer
... patients administered induction chemotherapy for acute leukemias develop potentially life-threatening infections. Infectious complications caused death in up to 70% of patients treated for acute leukemia. A variety of effective empiric antibiotic drug regimens have been developed to treat patients w ...
... patients administered induction chemotherapy for acute leukemias develop potentially life-threatening infections. Infectious complications caused death in up to 70% of patients treated for acute leukemia. A variety of effective empiric antibiotic drug regimens have been developed to treat patients w ...
... now established as effective anti-hypertensive drugs''1. They also prolong life and delay progression of cardiac failure'21. In treatment of hypertension for over 16 years and heart failure for over 10 years, information has accumulated not only on ACE inhibitors as a therapeutic class but also on a ...
Bad Pharma
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.